Another investigated tissue biomarker, the mutated tumor suppression gene phosphatase and tensin homolog (PTEN) was assessed in prostate cancer radiogenomics [124], along with whole-exome DNA (deoxyribonucleic acid) sequencing data [125]. This evidence concerns the gene PTEN and prostate carcinoma.